Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer
Brachytherapy (BT) monotherapy is a well-established treatment modality for favorable intermediate risk (FIR) prostate cancer. However, patients with unfavorable intermediate risk (UIR) disease are often recommended trimodality therapy involving BT, androgen deprivation therapy (ADT), and external beam radiation therapy (EBRT). We sought to investigate the relative benefit of supplemental therapies (ADT and/or EBRT) for FIR and UIR prostate cancer in a large dataset.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Martin T. King, Ming-Hui Chen, Brian J. Moran, Michelle H. Braccioforte, Ivan Buzurovic, Vinayak Muralidhar, David D. Yang, Kent W. Mouw, Phillip M. Devlin, Anthony V. D ’Amico, Paul L. Nguyen, Peter F. Orio Tags: Original article Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | External Beam Therapy | Prostate Cancer | Radiation Therapy | Urology & Nephrology